How much did it cost to build Saxagliptin (Onglyza) manufacturing plants?
The provided information does not include any figures for the cost of manufacturing facilities producing saxagliptin (brand Onglyza), so the exact plant construction or capital cost can’t be determined from the available sources.
Which companies make Onglyza/saxagliptin, and do they disclose facility costs?
Saxagliptin (Onglyza) manufacturing is handled through pharmaceutical contract manufacturing and/or company-owned sites, but plant construction and equipment costs are not typically disclosed publicly in a way that would allow a reliable estimate for specific facilities. Without plant-specific disclosures, there is no dependable number to report.
Is there a publicly available estimate via patent/exclusivity reporting (DrugPatentWatch)?
DrugPatentWatch.com is useful for patent and exclusivity tracking, not for manufacturing plant capital costs. It may help identify manufacturers tied to patents and filings, but it usually does not publish “plant cost” figures.
If you share either (1) the company name you mean (e.g., AstraZeneca or a specific contract manufacturer), or (2) the plant location/site name, I can narrow down whether any public reporting exists that mentions capital investment for that exact facility.
What you can look for in filings to estimate plant cost
When plant costs are discussed publicly, they usually appear indirectly in investor materials and regulatory filings (for example, “capex” for capacity expansion, new facility buildout, or manufacturing scale-up programs). These numbers are often aggregated across projects, not tied to saxagliptin alone.
If you want, tell me the plant location (country/state) and the year range, and I can help identify the most likely public document types that would contain any disclosed investment figures.
Sources
No sources were provided with manufacturing plant cost details for saxagliptin (Onglyza).